A simplified liquid chromatography-mass spectrometry assay for artesunate and dihydroartemisinin, its metabolite, in human plasma

Molecules

Volumn 15, Issue 12, 2010, Pages 8747-8768

  Teja Isavadharm, Paktiya ^a   Siriyanonda, Duangsuda ^a   Siripokasupkul, Raveewan ^a   Apinan, Roongnapa ^a   Chanarat, Nitima ^a   Lim, Apassorn ^a   Wannaying, Srisombat ^a   Saunders, David ^a   Fukuda, Mark M ^a   Miller, Robert S ^b   Weina, Peter J ^b   Meléndez, Victor ^a  

^a U S ARMY   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Artesunate; Dihydroartemisinin; Human plasma; LC MS; Method validation

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROARTEMISININ;

ARTICLE; CHEMISTRY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; PLASMA; SENSITIVITY AND SPECIFICITY; TIME;

ANTIMALARIALS; ARTEMISININS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PLASMA; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 78650662099     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15128747     Document Type: Article

References (21)

1. WHO. Severe falciparum malaria. Trans. Roy. Soc. Trop. Med. Hyg. 2000, 94S1, 1-90.
2. WHO. WHO Guidelines for the treatment of malaria; World Health Organization: Geneva, Switzerland, 2006; http://www.who.int/malaria/docs/ TreatmentGuidelines2006.pdf/ (accessed on 3 December 2009)
3. Rosenthal, P.J. Artesunate for the treatment of severe falciparum malaria. New Eng. J. Med. 2008, 358, 1829-1836.
4. Kamchonwongpaisan, S.; Meshnick, S. The mode of action of the antimalarial artemisinin and its derivatives. Gen. Pharmacol. 1996, 27, 587-592.
5. Eckstein-Ludwig, U.; Webb, R.J.; Van Goethem, I.D.; East, J.M.; Lee, A.G,; Kimura, M.; O'Neill, P.M.; Bray, P.G.; Ward, S.A.; Krishna, S. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424, 6951-6957.
6. Day, N.; Dondorp, A.M. The management of patients with severe malaria. Am. J. Trop. Med. Hyg. 2007, 77 (6-Suppl.), 29-35.
7. Nosten, F.; White, N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 2007, 77 (6-Suppl.), 181-192.
8. Gu, Y.; Li, Q.; Melendez, V.; Weina, P. Comparison of HPLC with electrochemical detection and LC-MS/MS for the separation and validation of artesunate and dihydroartemisinin in animal and human plasma. J. Chromatogr. B 2008, 867, 213-218.
9. Lai, C.S.; Nair, N.K.; Mansor, S.M.; Olliaro, P.L.; Navaratnam, V. An analytical method with a single extraction procedure and two separate high performance liquid chromatographic systems for the determination of artesunate, dihydroartemisinin and mefloquine in human plasma for application in clinical pharmacological studies of the drug combination. J. Chromatogr. B 2007, 857, 308-314.
10. Naik, H.; Murry, D.J.; Kirsch, L.E.; Fleckenstein, L. Development and validation of a highperformance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma. J. Chromatogr. B 2005, 816, 233-242.
11. Van Quekelberghe, S.A.; Soomro, S.A.; Cordonnier, J.A.; Jansen, F.H. Optimization of an LCMS method for the determination of artesunate and dihydroartemisinin plasma levels using liquidliquid extraction. J. Anal. Toxicol. 2008, 32, 133-139.
12. Thuy le, T.D.; Hung le, N.; Danh, P.T.; Na-Bangchang, K. Development and validation of a liquid chromatography-mass spectrometry method for the simultaneous quantification of artesunate and dihydroartemisinin in human plasma. Southeast Asian J. Trop. Med. Public Health 2008, 39, 963-977.
13. Hanpithakpong, W.; Kamanikom, B.; Dondorp, A.M.; Singhasivanon, P.; White, N.J.; Day, N.P.; Lindegardh, N. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B 2008, 876, 61-68.
14. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation; Food and Drug Administration: Rockville, MD, USA, 2001.
15. ICH. Guidance for Industry, Q2B Validation of Analytical Procedures: Methodology; Food and Drug Administration: Rockville, MD, USA, 1996.
16. Cabri, W.; Ciogli, A.; D'Acquarica, I.; Di Mattia, M.; Galletti, B.; Gasparrini, F.; Giorgi, F.; Lalli, S.; Pierini, M.; Simone, P. On-column epimerization of dihydroartemisinin: An effective analytical approach to overcome the shortcomings of the International Pharmacopoeia monograph. J. Chromatogr. B 2008, 875, 180-191.
17. Haynes, R.K. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr. Top. Med. Chem. 2006, 6, 509-537.
18. Batty, K.T.; Thu, L.T.; Davis, T.M.; Ilett, K.F.; Mai, T.X.; Hung, N.C.; Tien, N.P.; Powell, S.M.; Thien, H.V.; Binh, T.Q.; Kim, N.V. A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 1998, 45, 123-129.
19. Davis, T.M.; Phuong, H.L.; Ilett, K.F.; Hung, N.C.; Batty, K.T.; Phuong, V.D.; Powell, S.M.; Thien, H.V.; Binh, T.Q. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 2001, 45, 181-186.
20. Li, Q.; Cantilena, L.R.; Leary, K.J.; Saviolakis, G.A.; Miller, R.S.; Melendez, V.; Weina, P.J. Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: A phase I study. Am. J. Trop. Med. Hyg. 2009, 81, 615-621.
21. Lindegardh, N.; Hanpithakpong, W.; Kamanikom, B.; Singhasivanon, P.; Socheat, D.; Yi, P.; Dondorp, A.M.; McGready, R.; Nosten, F.; White, N.J.; Day, N.P. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J. Chromatogr. B 2008, 876, 54-60.